Paying for pharmaceuticals: uniform pricing versus two-part tariffs

dc.contributor.authorBrekke, Kurt R.por
dc.contributor.authorDalen, Dag Mortenpor
dc.contributor.authorStraume, Odd Runepor
dc.date.accessioned2021-03-15T10:52:07Z
dc.date.available2021-03-15T10:52:07Z
dc.date.issued2021
dc.description.abstractTwo-part pricing (the Netflix model) has recently been proposed instead of uniform pricing for pharmaceuticals. Under two-part pricing the health plan pays a fixed fee for access to a drug at unit prices equal to marginal costs. Despite two-part pricing being socially efficient, we show that the health plan is worse off when the drug producer is a monopolist, as all surplus is extracted. This result is reversed with competition, as two-part pricing yields higher patient utility and lower drug costs for the health plan. However, if we allow for exclusive contracts, uniform pricing is preferred by the health plan.por
dc.description.sponsorshipThis paper is partly financed by National Funds of the FCT Portuguese Foundation for Science and Technology within the project UIDB/03182/2020.por
dc.distributioninternationalpor
dc.identifier.urihttps://hdl.handle.net/1822/70782
dc.language.isoengpor
dc.peerreviewednopor
dc.publisherUniversidade do Minho. Núcleo de Investigação em Políticas Económicas (NIPE)por
dc.relationUIDB/03182/2020por
dc.relationUIDP/03182/2020por
dc.relation.publisherversionhttps://www.eeg.uminho.pt/pt/investigar/nipe/Paginas/publicacoes.aspxpor
dc.rightsopenAccesspor
dc.subjectPharmaceuticalspor
dc.subjectHealth Planspor
dc.subjectPayment schemespor
dc.titlePaying for pharmaceuticals: uniform pricing versus two-part tariffspor
dc.typeworkingPaperpor
dspace.entity.typePublicationen
oaire.citationEndPage33por
oaire.citationIssueWP 01/2021por
oaire.citationStartPage1por

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
WP 1 2021.pdf
Tamanho:
868.61 KB
Formato:
Adobe Portable Document Format
Descrição:
Paying for pharmaceuticals: uniform pricing versus two-part tariffs